|
1 Indications And Usage Mavyret Is Indicated For The Treatment Of Adult And Pediatric Patients 12 Years And Older Or Weighing At Least 45 Kg With Chronic Hepatitis C Virus (Hcv) Genotype 1, 2, 3, 4, 5 Or 6 Infection Without Cirrhosis Or With Compensated Cirrhosis (Child-Pugh A). Mavyret Is Indicated For The Treatment Of Adult And Pediatric Patients 12 Years And Older Or Weighing At Least 45 Kg With Hcv Genotype 1 Infection, Who Previously Have Been Treated With A Regimen Containing An Hcv Ns5a Inhibitor Or An Ns3/4a Protease Inhibitor (Pi), But Not Both [See Dosage And Administration (2.2) And Clinical Studies (14) ] . Mavyret Is A Fixed-Dose Combination Of Glecaprevir, A Hepatitis C Virus (Hcv) Ns3/4a Protease Inhibitor, And Pibrentasvir, An Hcv Ns5a Inhibitor, And Is Indicated For The Treatment Of Adult And Pediatric Patients 12 Years And Older Or Weighing At Least 45 Kg With Chronic Hcv Genotype (Gt) 1, 2, 3, 4, 5 Or 6 Infection Without Cirrhosis Or With Compensated Cirrhosis (Child-Pugh A). Mavyret Is Indicated For The Treatment Of Adult And Pediatric Patients 12 Years And Older Or Weighing At Least 45 Kg With Hcv Genotype 1 Infection, Who Previously Have Been Treated With A Regimen Containing An Hcv Ns5a Inhibitor Or An Ns3/4a Protease Inhibitor, But Not Both. (1)
|